5:2 Sub-Division/Split of Equity shares: January 8, 2025 Record Date; Buy Pharma Stock?

With more than 40 years of experience in the Indian pharmaceutical industry, Jagsonpal Pharmaceuticals Limited is a well-known pharmaceutical firm. The company's extensive pharmacological portfolio focuses on the child care, dermatology, orthopaedics, and gynaecology sectors. With 20+ products in the top 5 brands in the molecular category and a wide pan-India presence, the firm has its headquarters in Delhi and is listed on the Bombay Stock Exchange (Scrip code: 507789) and National Stock Exchange Limited (JAGSNPHARM). Following the company's announcement of the record date for a 5:2 stock split, Jagsonpal Pharmaceuticals' shares closed Wednesday's trading session 3.64% down at Rs 687.25 a share, with a market capitalisation of Rs 1,824.37 Cr on the BSE.

Jagsonpal Pharmaceuticals Stock Split

"Pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that, the Board of Directors of the Company has passed the necessary resolution through Circular Resolution, on Tuesday, December 17, 2024 and has fixed the record date on Wednesday, January 8, 2025 for the purpose of Sub-division/Split of equity shares of the Company such that 1 (one) equity share having face value of Rs. 5/- (Rupees five only) each, fully paid-up, be sub-divided into such number of equity shares having face value of Rs. 2 (Rupee two only) each, fully paid- up, pursuant to the shareholders' approval received through postal ballot by way of electronic means on Wednesday, December 11, 2024," said Jagsonpal Pharmaceuticals in a stock exchange filing.

Jagsonpal Pharmaceuticals Financials

For the quarter ending September 30, 2024, Jagsonpal Pharmaceuticals Ltd. reported a 53.41% increase in net profit to Rs 11.46 crore, up from Rs 7.47 crore in the same period the previous year. Compared to the Rs 57.83 crore recorded in the same quarter previous year, the company's revenue for the quarter ending in September 2024 increased by 29.15% to Rs 74.69 crore. EBITDA increased by 68.61% from Rs. 10.64 crore in Q2FY24 to Rs. 17.94 crore in Q2FY25.

Jagsonpal Pharmaceuticals Share Price Target

"Jagson Pharma stock price is bearish on the Daily charts with strong resistance at 730. A Daily close below support of 670 could lead to a target of 583 in the near term," recommended A R Ramachandran, Independent Research Analyst.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.